Table 3.
Studies evaluating the efficacy of vedolizumab for the prevention of endoscopic postoperative recurrence in Crohn’s disease
| Year | Author | Endoscopic postoperative recurrence in the control group (%) | Endoscopic postoperative recurrence with vedolizumab n/N (%) |
|---|---|---|---|
| 2018 | Yamada [63] | Anti-TNFs (34%) | 15/20 (75%) |
| 2022 | Yanai [67] |
Anti-TNFs (40%) Ustekinumab (62%) |
13/39 (33%) |
| 2022 | Le Cosquer [68]† |
Anti-TNFs (24%) Ustekinumab (44%) |
2/7 (28%) |
| 2022 | Axelrad [72] |
Anti-TNF (27%) Ustekinumab (21%) |
4/27 (15%) |
| 2023 | Mañosa [166] | Ustekinumab (42%) | 8/20 (40%) |
| 2023 | D’Haens [167, 168] | Placebo | 22/43 (51%) |